The country of origin of Triamterene and Hydrochlorothiazide Capsules USP, in dosage form
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- Therefore, we find the mixing of the active ingredients, Triamterene and Hydrochlorothiazide with the inactive ingredients into the final dosage capsules in India results in a substantial transformation and the country of origin will be India.
Ruling text
In your letter dated July 31, 2026, you requested a country of origin ruling on Triamterene and Hydrochlorothiazide Capsules USP, in dosage form. Triamterene and Hydrochlorothiazide, imported in 37.5 mg/25 mg capsules, is a medicinal preparation containing Triamterene (a potassium-sparing diuretic) and Hydrochlorothiazide (a thiazide diuretic), as the active ingredients. It is indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone.
You stated that the active pharmaceutical ingredients (APIs), Triamterene and Hydrochlorothiazide, are manufactured in Italy and India, respectively. In India, these two APIs will be mixed with various inactive ingredients to produce the final Triamterene and Hydrochlorothiazide Capsules in dosage form. When determining the country of origin, the substantial transformation analysis is applicable. See, e.g., Headquarters Ruling Letter (“HQ”) H301619, dated November 6, 2018.
The test for determining whether a substantial transformation will occur is whether an article emerges from a process with a new name, character, or use different from that possessed by the article prior to processing. See Texas Instruments Inc. v. United States, 681 F.2d 778 (C.C.P.A. 1982). This determination is based on the totality of the evidence. See National Hand Tool Corp. v. United States, 16 C.I.T. 308 (1992), aff’d, 989 F.2d 1201 (Fed. Cir. 1993).
In determining whether a substantial transformation occurs in the manufacture of chemical products such as pharmaceuticals, CBP has consistently examined the complexity of the processing and whether the final article retains the essential identity and character of the raw material. To that end, CBP has generally held that the processing of pharmaceutical products from bulk form into measured doses does not result in a substantial transformation of the product.
See, e.g., Headquarters Ruling (“HQ”) 561975, dated April 3, 2002; HQ 561544, dated May 1, 2000; HQ 735146, dated November 15, 1993; HQ H267177, dated November 5, 2016; HQ H233356, dated December 26, 2012; and, HQ 561975, dated April 3, 2002. However, where the processing from bulk form into measured doses involves the combination of two or more APIs, and the resulting combination offers additional medicinal benefits compared to taking each API alone, CBP has held that a substantial transformation occurred.
See, e.g., HQ 563207, dated June 1, 2005. In this case, we note that the two separate APIs are mixed to create a combination drug that offers additional medicinal benefits compared to taking each API alone. Therefore, we find the mixing of the active ingredients, Triamterene and Hydrochlorothiazide with the inactive ingredients into the final dosage capsules in India results in a substantial transformation and the country of origin will be India.
This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA).
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N363897).